Contents of Circulating Extracellular Vesicles: Biomarkers in Colorectal Cancer Patients
NCT ID: NCT04523389
Last Updated: 2020-08-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
172 participants
OBSERVATIONAL
2020-07-01
2021-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The exosomes are of endosomal origin. They are composed of proteins, lipids, RNA and DNA, and they circulate in the bloodstream. They can be internalized by specific distant cells and thus deliver a functional message. It has recently been shown that tumor exosomes containing pro-metastatic factors form pre-metastatic niches, before the tumor cells actually arrive, while determining the metastatic organotropism of tumors. These properties are now opening up new avenues of research in tumor biomarkers. In recent years, several studies have highlighted different markers contained specifically in exosomes derived from cancer cells. Consequently, exosomes are considered as potential reservoirs of tumor biomarkers that could be clinically useful for the non-invasive diagnosis of cancer, with the advantage of being performed by liquid biopsy. The study of microRNA (miRNA) is of particular interest. Indeed, miRNAs are small non-coding RNAs (between 21 and 25 nucleotides) involved in the regulation of gene expression and which are frequently deregulated in cancer. Several studies underline that the variation of free miRNAs in the blood is correlated with the progression of the disease, particularly in colon cancer. However, the stability of free miRNAs is controversial. Therefore, exosomes represent a very advantageous means of transporting miRNAs in the blood, as they are able to protect miRNAs from degradation by RNAase.
The hypothesis of the project is that circulating exosomes derived from tumours contain markers including specific miRNAs that could be used as biomarkers of early prognosis (survival and progression), easily measured in blood samples from patients with colon cancer. But other molecules contained in exosomes could also be of interest.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Identification of New Diagnostic Protein Markers for Colorectal Cancer
NCT04394572
The Detection of Circulating Tumor Cells (CTCs) in Patients With Colorectal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
NCT02450422
Prognosis Predicting of CRC Patients Based on Morphology and Molecular Biomaker of CTC
NCT04912882
Predicting Local and Distant Recurrence in T1 Colorectal Cancer
NCT06314971
The Immunoscore as a Prognostic Marker for Patients With a Colorectal Cancer
NCT01688232
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
colorectal cancer
analysis (protein, lipid, RNA ...) of circulating exosomes, size and number
use of blood samples stored at the Ferdinand Cabanne Biological Resource Centre
Gathering additional information about the patient's cancer
Gathering additional information about the patient's cancer, its treatment and its sequelae from the patient's medical record.
Diagnostic test
Diagnostic test
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
analysis (protein, lipid, RNA ...) of circulating exosomes, size and number
use of blood samples stored at the Ferdinand Cabanne Biological Resource Centre
Gathering additional information about the patient's cancer
Gathering additional information about the patient's cancer, its treatment and its sequelae from the patient's medical record.
Diagnostic test
Diagnostic test
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Person who provided consent or non-opposition to inclusion in the study
* Available blood sample in the AGARIC biobank at the Biological Resource Centre (Dijon)
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire Dijon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Chu Dijon Bourgogne
Dijon, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COTTET 2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.